376 related articles for article (PubMed ID: 29755456)
1. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
Mizui M; Tsokos GC
Front Immunol; 2018; 9():786. PubMed ID: 29755456
[TBL] [Abstract][Full Text] [Related]
2. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
Humrich JY; Riemekasten G
Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T Cells in SLE: Biology and Use in Treatment.
Giang S; La Cava A
Curr Rheumatol Rep; 2016 Nov; 18(11):67. PubMed ID: 27704250
[TBL] [Abstract][Full Text] [Related]
4. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
Front Immunol; 2019; 10():2606. PubMed ID: 31781109
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells in systemic lupus erythematosus.
Ohl K; Tenbrock K
Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].
Ohl K; Tenbrock K
Z Rheumatol; 2016 Apr; 75(3):253-64. PubMed ID: 26975190
[TBL] [Abstract][Full Text] [Related]
7. Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives.
Costa N; Marques O; Godinho SI; Carvalho C; Leal B; Figueiredo AM; Vasconcelos C; Marinho A; Moraes-Fontes MF; Gomes da Costa A; Ponte C; Campanilho-Marques R; Cóias T; Martins AR; Viana JF; Lima M; Martins B; Fesel C
Clin Exp Immunol; 2017 Sep; 189(3):318-330. PubMed ID: 28542701
[TBL] [Abstract][Full Text] [Related]
8. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.
Valencia X; Yarboro C; Illei G; Lipsky PE
J Immunol; 2007 Feb; 178(4):2579-88. PubMed ID: 17277168
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose IL-2 in the Treatment of Lupus.
Mizui M; Tsokos GC
Curr Rheumatol Rep; 2016 Nov; 18(11):68. PubMed ID: 27734211
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells.
Banica LM; Besliu AN; Pistol GC; Stavaru C; Vlad V; Predeteanu D; Ionescu R; Stefanescu M; Matache C
Int J Rheum Dis; 2016 Dec; 19(12):1294-1303. PubMed ID: 25351606
[TBL] [Abstract][Full Text] [Related]
11. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.
Zhao C; Chu Y; Liang Z; Zhang B; Wang X; Jing X; Hao M; Wang Y; An J; Zhang X; Sun L; Chen J
BMC Immunol; 2019 Sep; 20(1):32. PubMed ID: 31484501
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T-cell levels in systemic lupus erythematosus patients: a meta-analysis.
Zhu Y; Huang Y; Ming B; Wu X; Chen Y; Dong L
Lupus; 2019 Apr; 28(4):445-454. PubMed ID: 30744525
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.
Tsai YG; Liao PF; Hsiao KH; Wu HM; Lin CY; Yang KD
Front Immunol; 2023; 14():1230264. PubMed ID: 37771588
[TBL] [Abstract][Full Text] [Related]
14. [IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].
Humrich JY; Riemekasten G
Z Rheumatol; 2016 Jun; 75(5):490-2. PubMed ID: 27250490
[No Abstract] [Full Text] [Related]
15. T-regulatory cells in systemic lupus erythematosus.
La Cava A
Lupus; 2008 May; 17(5):421-5. PubMed ID: 18490420
[TBL] [Abstract][Full Text] [Related]
16. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE).
Bonelli M; Savitskaya A; von Dalwigk K; Steiner CW; Aletaha D; Smolen JS; Scheinecker C
Int Immunol; 2008 Jul; 20(7):861-8. PubMed ID: 18469329
[TBL] [Abstract][Full Text] [Related]
17. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus.
Humrich JY; Riemekasten G
Curr Opin Rheumatol; 2019 Mar; 31(2):208-212. PubMed ID: 30562181
[TBL] [Abstract][Full Text] [Related]
18. The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis.
Li W; Deng C; Yang H; Wang G
Front Immunol; 2019; 10():159. PubMed ID: 30833946
[No Abstract] [Full Text] [Related]
19. Analysis of FOXP3
Schmidt A; Rieger CC; Venigalla RK; Éliás S; Max R; Lorenz HM; Gröne HJ; Krammer PH; Kuhn A
Immunol Res; 2017 Apr; 65(2):551-563. PubMed ID: 28224362
[TBL] [Abstract][Full Text] [Related]
20. Foxp3, Regulatory T Cell, and Autoimmune Diseases.
Tao JH; Cheng M; Tang JP; Liu Q; Pan F; Li XP
Inflammation; 2017 Feb; 40(1):328-339. PubMed ID: 27882473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
